HSDT / Helius Medical Technologies, Inc. (HSDT) CEO Dane Andreeff on Q4 2021 Results - Earnings Call Transcript

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient T more_horizontal

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation techno more_horizontal

Helius Medical Technologies (NASDAQ: HSDT ) stock is rising higher on Tuesday as investors react to the neurotechnology company regaining listing com more_horizontal

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Michelle Bilski - In more_horizontal

Helius Medical Technologies, Inc. (HSDT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.11. Thi more_horizontal

NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech compa more_horizontal

Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech com more_horizontal

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Michelle Bilski - In-S more_horizontal